SCHEMBL725933

SCHEMBL725933

N[C@H](CO)[C@H](O)c1ccc([N+](=O)[O-])cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.55
CYP3A4 P08684 2/20 0.55
LMNA P02545 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
MARS2 Q96GW9 1/20 0.55
TSHR P16473 1/20 0.55
CYP2C19 P33261 1/20 0.55
MMP2 P08253 3/20 0.52
RPLP1 P05386 1/20 0.50
RPLP0 P05388 1/20 0.50
RPS17 P08708 1/20 0.50
RPSA P08865 1/20 0.50
RPS2 P15880 1/20 0.50
RPL35A P18077 1/20 0.50
RPL7 P18124 1/20 0.50
RPL17 P18621 1/20 0.50
RPS4Y1 P22090 1/20 0.50
RPS3 P23396 1/20 0.50
RPS12 P25398 1/20 0.50
RPL13 P26373 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL334444 1.00 ALDH1A1 (0.55) ALDH1A1CYP3A4LMNASMN1; SMN2MARS2
SCHEMBL251728 1.00 ALDH1A1 (0.55) ALDH1A1CYP3A4LMNASMN1; SMN2MARS2
SCHEMBL29167395 1.00 ALDH1A1 (0.55) ALDH1A1CYP3A4LMNASMN1; SMN2MARS2
SCHEMBL12172739 1.00 ALDH1A1 (0.55) ALDH1A1CYP3A4LMNASMN1; SMN2MARS2
SCHEMBL14183583 1.00 ALDH1A1 (0.55) ALDH1A1CYP3A4LMNASMN1; SMN2MARS2
SCHEMBL4247918 1.00 ALDH1A1 (0.55) ALDH1A1CYP3A4LMNASMN1; SMN2MARS2
SCHEMBL4406664 1.00 ALDH1A1 (0.55) ALDH1A1CYP3A4LMNASMN1; SMN2MARS2
SCHEMBL3912679 1.00 ALDH1A1 (0.55) ALDH1A1CYP3A4LMNASMN1; SMN2MARS2
Hydrochloric Acid SCHEMBL11703545 0.98 ALDH1A1 (0.54) ALDH1A1CYP3A4LMNASMN1; SMN2MARS2
Hydrochloric Acid SCHEMBL10626955 0.98 ALDH1A1 (0.54) ALDH1A1CYP3A4LMNASMN1; SMN2MARS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 238 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3694864-B1 BORONIC ACID DERIVATIVES AND SYNTHESIS THEREOF QPEX BIOPHARMA INC (US) 2025-03-05 EP claimed
US-12233182-B2 Instant underwater bio-adhesive containing catechol moieties and water-resistant cholesterol CITY UNIVERSITY OF HONG KONG (HK) 2025-02-25 US claimed
CN-117677605-B Process for preparing levetiracetam and intermediates thereof 苏州博希康医药科技有限公司 2025-01-10 CN claimed
US-20240108782-A1 AN INSTANT UNDERWATER BIO-ADHESIVE CONTAINING CATECHOL MOIETIES AND WATER-RESISTANT CHOLESTEROL CITY UNIVERSITY OF HONG KONG (HK) 2024-04-04 US claimed
CN-117677605-A Process for preparing levetiracetam and intermediates thereof 维生源知识产权有限责任公司 2024-03-08 CN claimed
CN-117185938-A Preparation process of (1R, 2R) -2-amino-1- (4-nitrophenyl) -1, 3-propanediol 宁波酶赛生物工程有限公司 2023-12-08 CN claimed
US-11286270-B2 Boronic acid derivatives and synthesis thereof QPEX BIOPHARMA, INC. (US) 2022-03-29 US claimed
US-20200407373-A1 BORONIC ACID DERIVATIVES AND SYNTHESIS THEREOF QPEX BIOPHARMA, INC. 2020-12-31 US claimed
US-9737875-B2 Affinity reagents for protein purification IMPOSSIBLE FOODS INC. (US) 2017-08-22 US claimed
EP-1644384-B1 PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF ENTECAVIR BRISTOL MYERS SQUIBB CO (US) 2012-10-31 EP claimed
US-20060106215-A1 Process for preparing the antiviral agent [1S-(1alpha, 3alpha, 4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one CHAN YEUNG Y 2006-05-18 US claimed
EP-1644384-A2 PROCESS AND INTERMEDIATES FOR SYNTHESIS ENTECAVIR Bristol-Myers Squibb Company (US) 2006-04-12 EP claimed
JP-2006509800-A 2006-03-23 JP claimed
US-20060020022-A1 Enantioselective separation method PHARMACIA & UPJOHN COMPANY LLC 2006-01-26 US claimed
US-20050033084-A1 Resolution of alpha-(phenoxy)phenylacetic acid derivatives METABOLEX, INC. (US) 2005-02-10 US claimed
US-20050020834-A1 Method for preparation of sulphostin and its analogue or intermediates thereof NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2005-01-27 US claimed
US-20040242921-A1 Resolution process for (r)-(-)-2-hydroxy-2-(2-chlorophenyl) acetic acid SANOFI (FR) 2004-12-02 US claimed
US-20040192912-A1 Process for preparing the antiviral agent [1S-(1alpha,3 alpha,4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one BRISTOL-MYERS SQUIBB COMPANY 2004-09-30 US claimed
EP-1457494-A1 PROCESSES FOR PREPARATION OF SULPHOSTIN AND ITS ANALOGUES OR INTERMEDIATES THEREOF Nippon Kayaku Kabushiki Kaisha (JP) 2004-09-15 EP claimed
WO-2004052310-A2 PROCESS AND INTERMEDIATES FOR SYNTHESIS ENTECAVIR BRISTOL-MYERS SQUIBB COMPANY (US) 2004-06-24 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050020834-A1 Method for preparation of sulphostin and its analogue or intermediates thereof SOST, PTMS, FGF23 ALDH1A1 3724/4885CYP3A4 2752/4885LMNA 1125/4885
US-20040242921-A1 Resolution process for (r)-(-)-2-hydroxy-2-(2-chlorophenyl) acetic acid GRHPR, HCAR2, HCAR1 ALDH1A1 126/4885CYP3A4 245/4885LMNA 3718/4885
US-20040192912-A1 Process for preparing the antiviral agent [1S-(1alpha,3 alpha,4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one SAMHD1, NUDT1, ENTPD1 ALDH1A1 1031/4885CYP3A4 588/4885LMNA 2046/4885
US-20200407373-A1 BORONIC ACID DERIVATIVES AND SYNTHESIS THEREOF BTD, BLVRB, BLK ALDH1A1 1025/4885CYP3A4 471/4885LMNA 562/4885
US-20050033084-A1 Resolution of alpha-(phenoxy)phenylacetic acid derivatives PAH, PDGFA, PDGFRA ALDH1A1 64/4885CYP3A4 691/4885LMNA 1939/4885
US-11286270-B2 Boronic acid derivatives and synthesis thereof BTD, BLVRB, BLK ALDH1A1 1025/4885CYP3A4 471/4885LMNA 562/4885
US-20060106215-A1 Process for preparing the antiviral agent [1S-(1alpha, 3alpha, 4beta)]-2-amino-1,9-dihydro-9-[4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl]-6H-purin-6-one SAMHD1, NUDT1, ENTPD1 ALDH1A1 976/4885CYP3A4 487/4885LMNA 2145/4885
US-20060020022-A1 Enantioselective separation method SLC7A1, SLC10A1, DHCR7 ALDH1A1 350/4885CYP3A4 86/4885LMNA 3541/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.